Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Axitinib/Pembrolizumab

Immune-related hepatitis and cytokine release syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yoshimura A, et al. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy. International Cancer Conference Journal 13 : 26-32, Jan 2024. Available from: URL: https://dx.doi.org/10.1007/s13691-023-00630-w [summarised from an abstract] Yoshimura A, et al. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy. International Cancer Conference Journal 13 : 26-32, Jan 2024. Available from: URL: https://dx.doi.org/10.1007/s13691-023-00630-w [summarised from an abstract]
Metadaten
Titel
Axitinib/Pembrolizumab
Immune-related hepatitis and cytokine release syndrome
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52769-0

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs